173 related articles for article (PubMed ID: 36699065)
1. Adding of apatinib and camrelizumab to overcome
Lv H; He Y; Nie C; Du F; Chen X
Front Pharmacol; 2022; 13():1067557. PubMed ID: 36699065
[No Abstract] [Full Text] [Related]
2. Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient.
Wang L; Li X; Cheng Y; Yang J; Liu S; Ma T; Luo L; Hu Y; Cai Y; Yan D
Front Immunol; 2021; 12():784861. PubMed ID: 35069555
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer.
Xu M; Meng X; Lu Y; Wang F
J Gastrointest Oncol; 2022 Apr; 13(2):548-558. PubMed ID: 35557572
[TBL] [Abstract][Full Text] [Related]
4. Significant effect of posterior line treatment of HER2 positive advanced gastric cancer: A case report.
Ma X; Xue L; Ou K; Liu X; Chen J; Gao L; Yang L
Heliyon; 2024 Apr; 10(7):e28923. PubMed ID: 38586326
[TBL] [Abstract][Full Text] [Related]
5. Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report.
Li X; Gu X; Xu J; Chen L; Li H; Meng D; Bai H; Yang J; Qian J
Onco Targets Ther; 2021; 14():3983-3989. PubMed ID: 34234467
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report.
Chen ZL; Zhao A; Li P; Zhang M; Yang J; Zhang L; Zhao X; Yang J; Wang L
Oncol Lett; 2018 Oct; 16(4):4614-4620. PubMed ID: 30214596
[TBL] [Abstract][Full Text] [Related]
7. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
[TBL] [Abstract][Full Text] [Related]
9. Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report.
Huang LT; Ma JT; Zhang SL; Li XH; Sun L; Jing W; Zhao JZ; Wang YR; Han CB
Front Oncol; 2019; 9():1453. PubMed ID: 31956604
[No Abstract] [Full Text] [Related]
10. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Tabernero J; Hoff PM; Shen L; Ohtsu A; Shah MA; Cheng K; Song C; Wu H; Eng-Wong J; Kim K; Kang YK
Lancet Oncol; 2018 Oct; 19(10):1372-1384. PubMed ID: 30217672
[TBL] [Abstract][Full Text] [Related]
11. The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review.
He L; Shen X; Liu Y; Gao L; Wu J; Yu C; Li G; Wang X; Shao X
Transl Cancer Res; 2022 Nov; 11(11):4206-4217. PubMed ID: 36523304
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab: a review of its use in HER2-positive advanced gastric cancer.
Sanford M
Drugs; 2013 Sep; 73(14):1605-15. PubMed ID: 24057416
[TBL] [Abstract][Full Text] [Related]
13. HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.
Jiao XD; Liu K; Wu Y; Zhou XC; Qin BD; Ling Y; Liu J; He X; Du H; Xiang J; Zang YS
Oncologist; 2021 Sep; 26(9):717-721. PubMed ID: 33896090
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment of apatinib for chemotherapy-refractory advanced gastric carcinoma with AFP-secretion and HER2-positivity: A case report.
Ding X; Ding J
Mol Clin Oncol; 2021 Aug; 15(2):151. PubMed ID: 34141430
[TBL] [Abstract][Full Text] [Related]
15. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases.
Al-Batran SE; Hozaeel W; Jäger E
Onkologie; 2012; 35(9):505-8. PubMed ID: 23007148
[TBL] [Abstract][Full Text] [Related]
16. Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report.
Huang J; Chen X; Guo J; Song L; Mu Y; Zhao H; Du C
Oncol Lett; 2023 Feb; 25(2):56. PubMed ID: 36644147
[TBL] [Abstract][Full Text] [Related]
17. Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer.
Pan Y; Lu L; Liu H; Chen D; Han N; Yao R; Wang X; Gao X; Yu J; Chen L; Zhou F; Hao G; Lu Y; Li M; He G; Kang F; Li Z; Tang Y; Zhang J; Wei L; Nie Y
Front Immunol; 2022; 13():1003859. PubMed ID: 36353623
[TBL] [Abstract][Full Text] [Related]
18. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
[TBL] [Abstract][Full Text] [Related]
19. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
Kawamoto Y; Yuki S; Meguro T; Hatanaka K; Uebayashi M; Nakamura M; Okuda H; Iwanaga I; Kato T; Nakano S; Sato A; Harada K; Oba K; Sakata Y; Sakamoto N; Komatsu Y
Oncologist; 2022 May; 27(5):340-e374. PubMed ID: 35303078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]